A scoping review protocol to elucidate outcomes following abiraterone versus enzalutamide for prostate cancer
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0273826
Abstract: Introduction Abiraterone acetate and enzalutamide are commonly employed in prostate cancer therapy in an interchangeable manner. These drugs are highly efficacious in androgen antagonism to improve patient outcomes, but they also carry noteworthy risk of… read more here.
Keywords: abiraterone; prostate cancer; following abiraterone; methodology ... See more keywords
Immediate Prostate-specific Antigen Decline After Enzalutamide Following Abiraterone Predicts Survival in Castration-resistant Disease
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15790
Abstract: Background/Aim: Although the sequential use of abiraterone and enzalutamide is not recommended because of possible cross-resistance, many patients with metastatic castration-resistant prostate cancer (mCRPC) are receiving sequential abiraterone and enzalutamide in the real world, and… read more here.
Keywords: decline; psa decline; abiraterone; castration resistant ... See more keywords